CNMD stock icon

CONMED
CNMD

$74.17
0.19%

Market Cap: $2.29B

 

About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

Employees: 4,000

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

5% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 106

0.02% more ownership

Funds ownership: 115.75% [Q1] → 115.77% (+0.02%) [Q2]

2% less funds holding

Funds holding: 293 [Q1] → 286 (-7) [Q2]

13% less capital invested

Capital invested by funds: $2.85B [Q1] → $2.47B (-$382M) [Q2]

16% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 43

47% less call options, than puts

Call options by funds: $4.18M | Put options by funds: $7.91M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$71
4%
downside
Avg. target
$86
16%
upside
High target
$106
43%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Piper Sandler
Matt O'Brien
50% 1-year accuracy
22 / 44 met price target
8%upside
$80
Overweight
Maintained
1 Aug 2024
Stifel
Rick Wise
68% 1-year accuracy
19 / 28 met price target
2%upside
$76
Buy
Maintained
1 Aug 2024
Wells Fargo
Vik Chopra
20% 1-year accuracy
1 / 5 met price target
4%downside
$71
Equal-Weight
Maintained
1 Aug 2024
Needham
Mike Matson
64% 1-year accuracy
72 / 113 met price target
31%upside
$97
Buy
Maintained
1 Aug 2024
Needham
Mike Matson
64% 1-year accuracy
72 / 113 met price target
43%upside
$106
Buy
Maintained
25 Jul 2024

Financial journalist opinion

Based on 6 articles about CNMD published over the past 30 days